Perfuze Receives FDA 510(k) Clearance for Millipede88 Aspiration Catheter

Why It Matters

The clearance introduces a novel, high‑performance aspiration tool that can shorten procedure times and improve first‑pass success, potentially reducing stroke morbidity and overall healthcare costs.

Key Takeaways

• First FDA‑cleared 0.088 catheter for standalone aspiration
• Corrugated architecture preserves lumen, enhancing navigation in tortuous vessels
• MARRS trial: 96% deliverability, 77% first‑pass reperfusion
• Direct aspiration reduces device count, lowering per‑case costs
• Limited U.S. release targets comprehensive stroke centers initially

Pulse Analysis

Mechanical thrombectomy has become the standard of care for acute ischemic stroke, yet procedural efficiency remains a critical challenge. Physicians rely on aspiration catheters to retrieve clots, but conventional designs can lose lumen shape when navigating the brain's winding vessels, compromising suction force. The market has seen incremental improvements, but a breakthrough that simultaneously simplifies navigation and maximizes aspiration power has been elusive. Against this backdrop, Perfuze’s FDA 510(k) clearance for the Millipede88 marks a notable shift, positioning the device as a potential new benchmark for stroke intervention.

The Millipede88’s distinguishing feature is its corrugated catheter architecture, which maintains a consistent inner lumen even in highly tortuous neurovascular pathways. This design prevents the ovalization that plagues traditional catheters, ensuring that aspiration force remains at the clot face. In the MARRS trial, the catheter achieved a 96% deliverability rate and a 77% first‑pass reperfusion rate in M1 occlusions—metrics that surpass most peers in independently adjudicated studies. By enabling physicians to achieve reperfusion on the first pass, the device can shave critical minutes off door‑to‑reperfusion times, directly impacting neuronal survival and patient outcomes.

From a business perspective, the clearance gives Perfuze entry into the super‑bore aspiration segment, a space previously dominated by a handful of legacy players. The limited market release at comprehensive stroke centers serves as a real‑world validation phase, while broader commercialization promises to capture market share from competitors lacking a comparable 0.088 corrugated solution. If adoption scales, Perfuze could see accelerated revenue growth and strengthen its position as an innovator in neurovascular devices, while hospitals benefit from reduced procedural complexity and lower per‑case device costs.